SETDB2 is a histone methyltransferase that catalyzes trimethylation of histone H3 lysine 9 (H3K9me3), a repressive chr13 mark essential for transcriptional silencing 12. The enzyme plays critical roles in early embryonic development, particularly in left-right axis specification, with genetic variants in SETDB2 associated with handedness in humans 3. SETDB2 functions as an epigenetic regulator across multiple pathological contexts. In cancer, it contributes to therapy-induced cellular reprogramming and drug resistance through increased H3K9me3 deposition 2, while showing differential expression patterns in renal cell carcinoma subtypes that correlate with prognosis and metastasis risk 4. In inflammatory diseases, SETDB2 suppresses NF-κB-mediated inflammation in macrophages during wound repair, with STAT3 regulating both its expression and activity 1. The enzyme also controls matrix metalloproteinase activity in abdominal aortic aneurysms by epigenetically silencing tissue inhibitors of metalloproteinases 5. In diabetic kidney disease, SETDB2 protects podocyte function by repressing SMAD3 expression through H3K9me3 modification 6. These diverse functions position SETDB2 as a critical epigenetic regulator linking chr13 modification to disease pathogenesis.